___

• Abdualmjid RJ, Sergi C (2013). Hepatotoxic botanicals-An evidence- based systematic review. J Pharm Pharm Sci 16(3): 376–404. [CrossRef ] • Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y (2014). Human drug-induced liver injury severity is highly associated to dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 60:1015–1022. [CrossRef ] • Björnsson E (2016). Hepatotoxicity by drugs: the most common ımplicated agents. Int J Mol Sci 17(2): 224. [CrossRef ] • Björnsson ES, Hoofnagle JH (2016). Categorization of drugs implicated in causing liver injury: Critical assessment based on published case reports. Hepatology 63(2): 590–603. [CrossRef ] • Boelsterli UA, Lim PLK (2007). Mitochondrial abnormalities-a link to idiosyncratic drug hepatotoxicity? Toxicol Appl Pharm 220(1): 92–107. [CrossRef ] • Bunchorntavakul C, Reddy KR (2013). Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther 37(1): 3–17. [CrossRef ] • Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J (2008). Causes, clinical features, and outcomes from a prospective study of drug-ınduced liver ınjury in the United States. Gastroenterology 135(6): 1924–1934. [CrossRef ] • Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI (2015). Druginduced liver injury: interactions between drug properties and host factors. J Hepatol 63(2): 503–514. [CrossRef ] • Clinical P (2009). Guidance for industry drug-induced liver injury: premarketing clinical evaluation. Drug Safety July, 28. Dağ MS, Aydınlı M, Öztürk ZA, Türkbeyler IH, Koruk I, Savaş MC, Koruk M, Kadayıfçı A (2014). Drug- and herb-induced liver injury: a case series from a single center. Turk J Gastroenterol 25: 41–45. [CrossRef ] • Daly AK (2012) Genetic polymorphisms affecting drug metabolism: Recent advances and clinical aspects. Adv. Pharmacol. 63: 137–167. [CrossRef ] • Dara L, Hewett J, Lim JK (2008). Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol 14(45): 6999–7004. [CrossRef ] • Federal Register. (2012). Patient protection and affordable care act; standards related to essential health benefits, actuarial value, and accreditation. Department of Health and Human Services, Part V, 77 (227): 70644–70676. • Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J (2009). Drug-induced liver injury network (DILIN) prospective study: rationale, design and conduct. Drug Safety 32(1): 55–68. [CrossRef ] • Garcia-Cortes M , Stephens C, Lucena M, Fernandez-Castaner A ,Andrade R.J (2011). Causality assessment methods in drug induced liver injury: Strengths and weaknesses. J Hepatol55: 683–691. [CrossRef ] • Gómez-Lechón MJ, Tolosa L, Donato MT (2015). Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs. J Appl Toxicol 36(6): 752-768. [CrossRef ] • Hussaini SH, Farrington EA (2014). Idiosyncratic drug-induced liver injury: an update on the 2007 overview. Expert Opin Drug Saf 13(1): 67–81. [CrossRef ] • Korth C (2014). Drug-induced hepatotoxicity of select herbal therapies. J Pharm Pract 27(6): 567–72. [CrossRef ] • Köck K, Ferslew BC, Netterberg I, Yang K, Urban TJ, Swaan PW, Stewart PW, Brouwer KL. (2014). Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos 42: 665–674. [CrossRef ] • Kramer JR, Giordano TP, Souchek J, El-Serag HB. (2005). Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol 42(3): 309–314. [CrossRef ] • Larrey D, Vial T, Pauwels A (1992). Hepatitis after germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity. Ann Intern Med 117: 129–32 [CrossRef ] • Larrey D, Faure S (2011). Herbal medicine hepatotoxicity: a new step with development of specific biomarkers. J Hepatol 54(4): 599–601. [CrossRef ] • Lee WM (2003). Drug-induced hepatotoxicity. N Eng J Med 349: 474–485. [CrossRef ] • Navarro VJ, Lucena MI (2014). Hepatotoxicity induced by herbal and dietary supplements. Semin Liver Dis 34(2): 172–193. [CrossRef ] • Njoku DB (2014). Drug-induced hepatotoxicity: metabolic, genetic and immunological basis. Int J Mol Sci 15(4): 6990–7003. [CrossRef ] • Oh SJ, Cho JH, Son CG (2015). Systematic review of the incidence of herbal drug-induced liver injury in Korea. J Ethnopharmacol 159: 253–256. [CrossRef ] • Russo MW, Galanko JA, Shrestha R (2004). Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 10(10) :18-235. [CrossRef ] • Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, Hillon P (2002). Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36(2): 451–455. [CrossRef ] • Spengler U, Lichterfeld M, Rockstroh JK (2002). Antiretroviral drug toxicity-a challenge for the hepatologist? J Hepatol 36(2): 283–294. [CrossRef ] • Suk KT, Kim DJ (2012). Drug-induced liver injury: present and future. Clin Mol Hepatol 18(3): 249. [CrossRef ] • Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS (2011). Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol 24:1345–1410. [CrossRef ] • Temple R (2006). Hy’s law : predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 15(4): 241–243. [CrossRef ] • Teschke R, Eickhoff A (2015). Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps. Front Pharmacol 6: 1–40. [CrossRef ] • Teschke R, Schwarzenboeck A, Eickhoff A, Frenzel C, Wolff A, Schulze J. (2013). Clinical and causality assessment in herbal hepatotoxicity. Expert Opin Drug Saf 12(3): 339–366. [CrossRef ] • Vree JM, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, Deleuze JF, Desrochers M, Burdelski M, Bernard O, Elferink RPJO, Hadchouel M (1998). Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA 95: 282–287. [CrossRef ] • Wu CP, Hsieh CH, Wu YS (2011). The emergence of drug transporter- mediated multidrug resistance to cancer chemotherapy. Mol Pharm 8: 1996–2011. [CrossRef ]